MiNK Therapeutics Inc. (INKT) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, MiNK Therapeutics Inc. (NASDAQ: INKT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $10.88 (+0.69% 1D, market cap $55.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INKT ranks #466 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INKT carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ELOX (Eloxx Pharmaceuticals Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $53.3M) and KLRS (Kalaris Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $50.7M). Among the 5-stock peer group, INKT leads on earnings multiple (N/A) while INKT leads on capital efficiency (-35.0% ROIC).
Per INKT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840229), MiNK Therapeutics Inc. generated $0 in revenue, -$12.5M in net income, and -$5.9M in free cash flow against $14.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 28% of 52W Range • RSI-14 at 46.1 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While INKT currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.35) and Max Pain ($11.42) forces dealer call-delta covering toward $17.78.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
MiNK Therapeutics Inc. (INKT) advanced +0.69% to $10.88, trading at 28% of its 52-week range ($8.48 – $16.93). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
B. Riley Securities analyst Mayank Mamtani reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and raises the price target from $43 to $50.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INKT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INKT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, MiNK Therapeutics Inc. (INKT) ranks #466 by composite RQD confidence (43/100, grade D-) and #735 by equity capitalization ($55.5M). Within this direct 5-issuer industry benchmark cohort, INKT leads on earnings valuation at N/A trailing P/E, while INKT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INKT currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INKT
ACTIVE
MiNK Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | +0.69% | $55.5M | Benchmark Subject |
| ELOX Eloxx Pharmaceuticals Inc. | D- | 42/100 | — | — | -35.0% | +0.61% | $53.3M | /elox-vs-inkt → |
| KLRS Kalaris Therapeutics Inc. | E | 31/100 | — | — | -35.0% | +5.97% | $50.7M | /klrs-vs-inkt → |
| PTHS Pelthos Therapeutics Inc. | E | 34/100 | — | 76.3% | -35.0% | +5.08% | $63.3M | /pths-vs-inkt → |
| CRBU Caribou Biosciences Inc. | E | 33/100 | — | — | -35.0% | -9.07% | $47.7M | /crbu-vs-inkt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), MiNK Therapeutics Inc. (INKT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.5M, operating cash flow of -$5.9M, and free cash flow of -$5.9M (+38.0% YoY). On the balance sheet, INKT closed FY2025 with $14.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$12.5M | -$5.9M | -$5.9M | $14.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$10.8M | -$9.6M | -$9.6M | $5.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$22.5M | -$15.8M | -$15.8M | — | — |
As of 2026-11-02, MiNK Therapeutics Inc. (NASDAQ: INKT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $10.88 (+0.69% 1D, market cap $55.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INKT ranks #466 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INKT carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ELOX (Eloxx Pharmaceuticals Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $53.3M) and KLRS (Kalaris Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $50.7M). Among the 5-stock peer group, INKT leads on earnings multiple (N/A) while INKT leads on capital efficiency (-35.0% ROIC).
Per INKT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840229), MiNK Therapeutics Inc. generated $0 in revenue, -$12.5M in net income, and -$5.9M in free cash flow against $14.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
INKT last traded at $10.88 (+0.69% on volume of 9,774 shares), positioning the stock -4.14% below its 50-day simple moving average ($11.35) and -3.63% below its 200-day simple moving average ($11.29). Across its 52-week range of $8.48 to $16.93, INKT sits at the 28.4% percentile with a 14-day RSI of 46.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.52 to $12.24).
Why INKT Stock advanced +0.69% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).